Compare RICK & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RICK | CGEN |
|---|---|---|
| Founded | 1983 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.0M | 220.7M |
| IPO Year | 1995 | 2000 |
| Metric | RICK | CGEN |
|---|---|---|
| Price | $24.85 | $2.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $98.00 | $4.00 |
| AVG Volume (30 Days) | 88.4K | ★ 591.3K |
| Earning Date | 02-09-2026 | 03-03-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | ★ 252.84 | N/A |
| EPS | ★ 1.86 | N/A |
| Revenue | ★ $281,738,000.00 | $6,903,000.00 |
| Revenue This Year | $3.62 | N/A |
| Revenue Next Year | $8.86 | $164.92 |
| P/E Ratio | $13.46 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.88 | $1.13 |
| 52 Week High | $57.99 | $2.66 |
| Indicator | RICK | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 66.02 |
| Support Level | $24.04 | $2.04 |
| Resistance Level | $27.01 | $2.38 |
| Average True Range (ATR) | 1.13 | 0.15 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 43.13 | 73.64 |
RCI Hospitality Holdings Inc through its subsidiaries owns and operates establishments that offer live adult entertainment, restaurant, and or bar operations. It also owns and operates a communication company serving the adult nightclub industry. The company's operating business segments are Nightclubs, Bombshells, and Others. It operates nightclubs through the following brands Rick's Cabaret, Vivid Cabaret, Tootsie's Cabaret, Club Onyx, and Jaguars Club. In the Bombshells segment, the company is building a chain of Restaurants and Sports Bars in Dallas, Austin, and Houston, Texas. It derives the majority of revenue from the Nightclubs segment that engages in the sale of alcoholic beverages, food, and merchandise items; service in the form of cover charges, dance fees, and room rentals.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.